Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate anti-tumor safety and efficacy of endostar®（Human
recombinant endostatin injection）combined with traditional GDP
（gemcitabine+dexamethasone+cis-platinum）chemotherapy for newly diagnosed or relapsed
PTCL(aggressive peripheral T-cell lymphomas) patients in phase II clinical study.
Phase:
Phase 2
Details
Lead Sponsor:
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Collaborator:
Jiangsu Cancer Institute & Hospital
Treatments:
Cisplatin Dexamethasone Endostar protein Gemcitabine